These results demonstrate that Nrf2 plays a critical role in regulating insulin sensitivity in the heart but presumably also in other tissue districts; therefore, targeting Nrf2 might provide a novel therapeutic approach for the treatment of insulin resistance and diabetic cardiomyopathy [43]. The gene discussed is NFE2L2; the disease is diabetic cardiomyopathy.